Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John Metcalf who wrote (792)	6/3/1997 9:45:00 PM
From: Jorgen Jensen	of 6136

John, The playing field seems to be getting crowded: * BRISTOL MYERS SQUIBB CO acquired worldwide development and marketing rights for two protease inhibitors from Novartis Pharma AG. Bristol said it would start Phase II clinical trials on one of the drugs, known as BMS-234475 (formerly CGP-61755). The peptidomimetic protease inhibitor is in the same class as the other protease inhibitors on the market -- Roche's saquinavir, MERCK's indinavir, ABBOTT LABS's ritonavir and AGOURON PHARMACEUTICALS INC.'s nelfinavir. (Reuters 07:30 AM ET 06/03/97) For the full text story, see merc.com What do you make of this? Richard? Anyone?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next